Burroughs Wellcome Co.

The Wellcome Foundation Limited

Sooft Italia Spa

Kemin Industries, Inc.

Over S.r.l.

Dr. Rolf Lambert Pharma-consulting Gmbh

Laboratorio Farmacologico Milanese S.r.l.

Giovanni Cavallo

Ezio Tubaro

Pierre Roy

Fulvio Foschini

Edoardo Stagni

Diogo De Sousa Martins

Giulio Luciani

Adriano Spreafico

Annalisa Santucci

Natale Figura

Piero Biondi

Roberto Filippo Marcolongo

Marcello Stagni

Massimo Filippello

Marco Biondi

Eugenio Sodo

Ivo Panzeri

Rolf Lambert

It is described a complex of riboflavin into hydroxypropylated &#x3b2;-cyclodextrins as photosensitizer in the riboflavin-UV mediated cross-linking of corneal collage fibers and the relative ophthalmic compositions comprising it.

Cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia

Iontophoresis, a minimally-invasive methodology that uses a weak electric current to enhance penetration of ionized molecules into tissues, was found to be an effective technique for the intraocular delivery of large bioactive molecules, specifically lutein.

Intraocular delivery of bioactive molecules using iontophoresis

Pharmaceutical compositions for treating infection from. are described, containing, as the active ingredients, polysorbate and an antibiotic selected from clarithromycin, metronidazole and a mixture thereof. The invention also concerns the use of such compositions as anti-infective agents for theeradication treatment, in particular in a combined therapy with a second antibiotic agent and with a gastric proton pump inhibiting agent, or an antacid, or an Hreceptor antagonist, in a therapeutic protocol known as 'triple therapy' for the treatment of peptic ulcer.

[object Object]

Ocular iontophoresis device and method for delivering any ionized drug solution to the cornea includes: a reservoir containing a solution suitable to be positioned on the eye; an active electrode disposed in or on the reservoir; and a passive electrode suitable to be placed on the skin of the subject, elsewhere on the body; elements for irradiating the cornea surface with suitable light for obtaining corneal cross-linking after the drug delivery; wherein the reservoir and the active electrode are transparent to UV light and/or visible light and/or IR light. The method includes: positioning the iontophoretic device on the eye to be treated; driving the solution by a cathodic current applied for 0.5 to 5 min, at an intensity not higher than 2 mA; and thereafter irradiating, with UV light for 5 to 30 min at a power of 3 to 30 mW/cm; thereby obtaining the corneal cross-linking of the solution.

Device and method for corneal delivery of riboflavin by iontophoresis for the treatment of keratoconus

The invention relates to N-deacetyl-lysogangliosides and physiologically acceptable salts thereof, especially those of formula (I): ##STR1## wherein R represents --CH.dbd.CH(CH.sub.2)nCH.sub.3 or --CH.sub.2 CH.sub.2 (CH.sub.2)nCH.sub.3 ;

Di-N-acetyl lysoganglioside compositions

Di-N-deacetyl-lysogangliosides

A novel mono-sialo ganglioside derivative substantially identical chemically and physically with a product prepared by

Ganglioside derivatives

Growing community of inventors

Rome, Italy

Giovanni Cavallo